SEC Form 4: Greenfield Andrew J returned 23,484 shares to the company, closing all direct ownership in the company

$ABMD
Medical/Dental Instruments
Health Care
Get the next $ABMD alert in real time by email
SEC FORM 4 SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
X
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
Greenfield Andrew J

(Last) (First) (Middle)
C/O ABIOMED, INC.
22 CHERRY HILL DRIVE

(Street)
DANVERS MA 01923

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
ABIOMED INC [ NASD ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
VP, CHIEF COMMERCIAL OFFICER
3. Date of Earliest Transaction (Month/Day/Year)
12/22/2022
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock, $.01 par value 12/22/2022 D(1)(2) 23,484(3) D $0(1)(2) 0 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy) $99.62 12/22/2022 D(4)(5) 5,000 (4)(5) 05/24/2026 Common Stock 5,000 (4)(5) 0 D
Stock Option (right to buy) $134.51 12/22/2022 D(4)(5) 6,500 (4)(5) 05/15/2027 Common Stock 6,500 (4)(5) 0 D
Stock Option (right to buy) $381.97 12/22/2022 D(4)(5) 4,000 (4)(5) 05/16/2028 Common Stock 4,000 (4)(5) 0 D
Stock Option (right to buy) $266.39 12/22/2022 D(4)(5) 7,000 (4)(5) 05/30/2029 Common Stock 7,000 (4)(5) 0 D
Stock Option (right to buy) $223.9 12/22/2022 D(4)(5) 4,896 (4)(5) 05/29/2030 Common Stock 4,896 (4)(5) 0 D
Stock Option (right to buy) $283.88 12/22/2022 D(4)(5) 2,868 (4)(5) 05/25/2031 Common Stock 2,868 (4)(5) 0 D
Performance Stock Units $0 12/22/2022 A(6)(7) 27,458 (6)(7) (6)(7) Common Stock 27,458 (6)(7) 27,458 D
Performance Stock Units $0 12/22/2022 D(6)(7) 27,458 (6)(7) (6)(7) Common Stock 27,458 (6)(7) 0 D
Explanation of Responses:
1. Disposed in connection with transactions contemplated by the Agreement and Plan of Merger, dated as of October 31, 2022 (the "Merger Agreement"), by and among the Issuer, Johnson & Johnson ("Parent") and Athos Merger Sub, Inc. ("Merger Sub"), pursuant to which Merger Sub was merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a wholly owned subsidiary of Parent. As a result of the Merger, each outstanding share of common stock, par value $0.01 per share, of the Issuer (the "Issuer Share") was automatically converted into the right to receive (i) an amount in cash equal to $380.00 (the "Cash Amount"), plus (ii) one non-tradeable contingent value right (the "CVR"), representing the right to receive contingent payments of up to $35.00 per Issuer Share, payable upon the achievement of certain specified milestones set out in the Contingent Value Rights Agreement.
2. Pursuant to the Merger Agreement, each award of restricted stock units of the Issuer, excluding any award of restricted stock units with vesting subject to performance-based conditions ("Company RSU Award"), outstanding as of immediately prior to the Effective Time was canceled and converted into the right to receive (i) an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Company RSU Award and (B) the Cash Amount and (ii) one CVR per Issuer Share.
3. This number reflects unvested Company RSU Awards and shares of common stock. The Form 4 filed on December 20, 2022 for Andrew Greenfield inadvertently omitted unvested Company RSU Awards from the balance of non-derivative securities beneficially owned by the reporting person.
4. Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each option to purchase Issuer Shares that was outstanding and unexercised immediately prior to the Effective Time was canceled and converted into the right to receive: (1) with respect to each stock option with a per share exercise price less than the Cash Amount (an "In-the-Money Option"), (A) an amount in cash, without interest, equal to the product of (I) the aggregate number of Issuer Shares underlying such In-the-Money Option and (II) the excess, if any, of (x) the Cash Amount over (y) the per share exercise price of such In-the-Money Option and (B) one CVR per Issuer Share underlying such In-the-Money Option; and
5. (2) with respect to each stock option with a per share exercise price that was greater than or equal to the Cash Amount (an "Out-of-the-Money option"), upon each Valuation Point (as defined in the Merger Agreement) occurring after the Effective Time, an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Out-of-the-Money Option and (B) (I) the excess, if any, of (x) the Per Share Value Paid (as defined in the Merger Agreement) as of such Valuation Point over (y) the per share exercise price of such Out-of-the-Money Option, less (II) the amount of all payments previously received with respect to such Out-of-the-Money Option.
6. Pursuant to the Merger Agreement, each award of restricted stock units with vesting subject to performance-based conditions ("Company PSU Award") outstanding immediately prior to the Effective Time was canceled and converted into the right to receive (i) an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Company PSU Award (assuming (1) the actual level of performance for performance metrics for which the relevant performance period has been completed as of December 22, 2022 (the "Closing Date") and (2) the maximum level of performance under the terms of the applicable award agreement as in effect on the date of the Merger Agreement for performance metrics for which the relevant performance period has not been completed as of the Closing Date (subject, in the case of Company PSU Awards granted to the Chief Executive Officer of the Company, to a maximum level of performance of 200% of the target level of performance) and
7. (B) the Cash Amount, and (ii) one CVR for each Issuer Share underlying such Company PSU Award (assuming (1) the actual level of performance for performance metrics for which the relevant performance period has been completed as of the Closing Date and (2) the maximum level of performance under the terms of the applicable award agreement as in effect on the date of the Merger Agreement for performance metrics for which the relevant performance period has not been completed as the Closing Date (subject, in the case of Company PSU Awards granted to the Chief Executive Officer of the Company, to a maximum level of performance of 200% of the target level of performance)).
/s/ Michael Dube (by power of attorney) 12/27/2022
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Get the next $ABMD alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ABMD

DatePrice TargetRatingAnalyst
11/2/2022$235.00 → $380.00Underweight → Equal-Weight
Morgan Stanley
11/2/2022$355.00 → $388.00Buy → Hold
Deutsche Bank
10/13/2022$300.00Buy
Mizuho
4/6/2022$330.00Peer Perform
Wolfe Research
2/4/2022$292.00 → $275.00Underweight
Morgan Stanley
2/4/2022$345.00 → $325.00Market Perform
SVB Leerink
1/7/2022$269.00 → $292.00Underweight
Morgan Stanley
8/6/2021$335.00 → $375.00Market Perform
SVB Leerink
More analyst ratings

$ABMD
Press Releases

Fastest customizable press release news feed in the world

See more
  • Dr. Mehdi H. Shishehbor Appointed Chief Medical Officer of Inquis Medical

    Renowned vascular disease expert joins Silicon Valley clinical stage medical device company developing next-generation thrombectomy technology Inquis Medical also announces appointment of Bruce Shook, serial medtech entrepreneur, to Board of Directors REDWOOD CITY, Calif., July 12, 2023 (GLOBE NEWSWIRE) -- Inquis Medical, Inc., a privately held medical device company focused on peripheral vascular innovations, today announced the appointment of distinguished interventional cardiologist and scholar, Mehdi H. Shishehbor, DO, MPH, Ph.D., as Chief Medical Officer. Dr. Shishehbor is the President of University Hospitals Harrington Heart and Vascular Institute where he is the Angela and Ja

    $STIM
    $ABMD
    Medical/Dental Instruments
    Health Care
  • FDA Approves Impella ECP Pivotal Heart Pump and First Patients Enrolled in Pivotal Clinical Trial

    Abiomed (NASDAQ:ABMD) announces the United States Food and Drug Administration (FDA) has approved the version of Impella ECP that will be used in the Impella ECP Pivotal Trial, and the first two patients have been enrolled in the trial. Amir Kaki, MD, director of mechanical circulatory support at Ascension St. John Hospital in Detroit, led the procedures. This single-arm, prospective, multi-center trial will evaluate the rate of major adverse cardiovascular and cerebrovascular events (MACCE) in adult patients who receive Impella ECP support during an elective or urgent high-risk percutaneous coronary intervention (PCI). This press release features multimedia. View the full release here: htt

    $ABMD
    Medical/Dental Instruments
    Health Care
  • Steel Dynamics Set to Join S&P 500; Super Micro Computer to Join S&P MidCap 400

    NEW YORK, Dec. 19, 2022 /PRNewswire/ -- S&P MidCap 400 constituent Steel Dynamics Inc. (NASD:STLD) will replace Abiomed Inc. (NASD:ABMD) in the S&P 500 and Super Micro Computer Inc. (NASD:SMCI) will replace Steel Dynamics in the S&P MidCap 400 effective prior to the opening of trading on Thursday, December 22. S&P 500 constituent Johnson & Johnson (NYSE:JNJ) is acquiring Abiomed in a deal expected to close soon pending final conditions.  Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name  Action Company Name Ticker GICS Sector December 22, 2022 S&P 500 Addition Steel Dynamics STLD Materials S&P 500 Deletion

    $ABMD
    $JNJ
    $SMCI
    $SPGI
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Computer Manufacturing

$ABMD
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$ABMD
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$ABMD
SEC Filings

See more

$ABMD
Leadership Updates

Live Leadership Updates

See more
  • Dr. Mehdi H. Shishehbor Appointed Chief Medical Officer of Inquis Medical

    Renowned vascular disease expert joins Silicon Valley clinical stage medical device company developing next-generation thrombectomy technology Inquis Medical also announces appointment of Bruce Shook, serial medtech entrepreneur, to Board of Directors REDWOOD CITY, Calif., July 12, 2023 (GLOBE NEWSWIRE) -- Inquis Medical, Inc., a privately held medical device company focused on peripheral vascular innovations, today announced the appointment of distinguished interventional cardiologist and scholar, Mehdi H. Shishehbor, DO, MPH, Ph.D., as Chief Medical Officer. Dr. Shishehbor is the President of University Hospitals Harrington Heart and Vascular Institute where he is the Angela and Ja

    $STIM
    $ABMD
    Medical/Dental Instruments
    Health Care
  • MedTechVets Appoints Patrice Sutherland, Enterprise Executive Director at Integra LifeScience, as New Board Chairperson

    Succeeds Derek Herrera after two-year term Patrice Sutherland, enterprise executive director at Integra Life Sciences, has been appointed Chairperson of the Board of Directors for MedTechVets, a nonprofit organization that helps military Veterans transition and gain employment at Medical Technology and Life Science companies. This announcement is being made today during the Plenary Luncheon at AdvaMed's MedTech Conference 2022, which is taking place through Oct. 26 at the Boston Convention and Exhibition Center. A U.S. Army combat Veteran, Sutherland succeeds Derek Herrera and will assume the role on January 1, 2023. This press release features multimedia. View the full release here: https

    $ABMD
    Medical/Dental Instruments
    Health Care
  • Dr. Paula A. Johnson Joins Abiomed Board of Directors

    Abiomed (NASDAQ:ABMD) announces the appointment of Paula A. Johnson, MD, MPH, to the Abiomed Board of Directors, effective immediately. Dr. Johnson will serve as a member of the Governance and Nominating Committee of the board. Following the appointment of Dr. Johnson, the board now comprises nine active directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210428005332/en/Dr. Paula A. Johnson joins the Abiomed Board of Directors (Photo: Business Wire) "Dr. Johnson is known internationally as a leading expert in healthcare, medical research and health policy, especially for her work advancing the health of women," said Michae

    $ABMD
    Medical/Dental Instruments
    Health Care

$ABMD
Financials

Live finance-specific insights

See more
  • Abiomed Announces Second Quarter Revenue of $266 Million, up 11% in Constant Currency*, up 7% on a Reported Basis Year Over Year

    ABIOMED, Inc. (NASDAQ:ABMD), a leader in breakthrough heart, lung and kidney support technologies, today announces financial results for the quarter ended September 30, 2022. Second Quarter 2023 Financial Highlights: Revenue of $266 million, an increase of 11% in constant currency, or 7% on a reported basis. This represents Abiomed's 7th consecutive quarter of double-digit constant currency growth. Worldwide product revenue of $253 million, an increase of 11% in constant currency, or 7% on a reported basis. Within the quarter, procedural volumes were impacted in July due to extended physician vacations, coupled with ongoing hospital labor shortages. The company saw an improvement in pa

    $ABMD
    $JNJ
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
  • Johnson & Johnson to Acquire Abiomed

    Strengthens Johnson & Johnson's MedTech Business with the Addition of Abiomed, a World-Leader in Heart Recovery Transaction to Bring Lifesaving Innovations to More Patients with Unmet Need Expected to Enhance Johnson & Johnson's Near- and Long-Term Sales and Earnings Growth; Accretive to Adjusted Earnings beginning in 2024 Conference Call at 8:00 a.m. ET To Discuss Details of the Transaction Johnson & Johnson (NYSE:JNJ), the world's largest, most diversified healthcare products company, and Abiomed (NASDAQ:ABMD), a world leader in breakthrough heart, lung and kidney support technologies, today announced that they have entered into a definitive agreement under which Johnson & Johnson wil

    $ABMD
    $JNJ
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
  • Abiomed Second Quarter Fiscal 2023 Earnings and Conference Call Notification

    Abiomed, Inc. (NASDAQ:ABMD) announced that on Tuesday, November 1, 2022, the Company will release financial results for the second quarter of the fiscal year 2023. The Company will host a conference call to discuss the results on Tuesday, November 1, 2022 at 8:00 a.m. ET. Michael R. Minogue, Chairman, President and Chief Executive Officer and Todd Trapp, Chief Financial Officer, will host the conference call. To listen to the call live, please tune into the webcast via https://events.q4inc.com/attendee/493387843 or dial (844) 200-6205; the international number is (929) 526-1599 access code 367357. A replay of this conference call will be available until Tuesday, November 8, 2022. The repla

    $ABMD
    Medical/Dental Instruments
    Health Care

$ABMD
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more